samedan logo
 
 
 
spacer
home > ebr > summer 2019 > an answerable challenge
PUBLICATIONS
European Biopharmaceutical Review

An Answerable Challenge

While cancer and cardiovascular diseases continue to hold the top ranks of the causes of mortality in Europe and North America, we have become accustomed to the burden of disease from neurodegenerative conditions increasing, mostly as a consequence of population ageing. If one were to cast the net wider (not only focusing on conditions that have neurodegeneration as a cause, but all neurological disorders), one would see that these were the leading cause of disability-adjusted life years − which refer to the sum of lost life years and years lived with disability − worldwide in 2016. While infectious causes have decreased over the past 25 years, stroke and dementia continue to loom large across the globe (1). In high-income countries, these two conditions rank second and third respectively in terms of crude death rate.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
While cancer and cardiovascular diseases continue to hold the top ranks of the causes of mortality in Europe and North Dr Hermann Mucke is the owner and Chief Executive of H.M. Pharma Consultancy, a globally acting provider of consulting services to the pharmaceutical industry and academia, with headquarters in Vienna, Austria. After earning his Master’s and PhD degrees in biochemistry and molecular biology, he spent four years at the University of Vienna, Austria, before moving to industry, finally becoming an entrepreneur in 2000 when he set up his life sciences consultancy. An expert in drug repurposing, patenting, and knowledge management, Hermann has assisted companies of all sizes over the past 20 years.
spacer
Dr Hermann Mucke
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Brooks Introduces Azenta Life Sciences To Advance Innovative Sample Solutions

CHELMSFORD, Mass., Sept. 28, 2021 -- Today Brooks Automation, Inc. (Nasdaq: BRKS) announces Brooks Life Sciences Services and Products businesses will be rebranded under the creation of a new identity – Azenta Life Sciences ("Azenta").
More info >>

White Papers

Cold-chain Bioprocessing Readiness: Mitigating Risk and Protecting Pharmaceutical Products

Entegris

The pharmaceutical industry is migrating rapidly toward a world where drugs, vaccines, and specialized therapies are available on demand to patients anywhere around the globe. Whether accelerating clinical trials to bring new drugs to market or devel oping biosimilars to give more patients access to established commercial drugs, small and midsize production facilities stand to benefit from growing demand. To do so, however, they must be prepared to handle a broader mix of products and increase throughput without sacrificing safety or reliability, while at the same time keeping life-saving medica tions affordable. Such challenges become more difficult when working with products that must be stored and shipped in a frozen state.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement